Business & regional news

Japan is now the 77th country to receive regulatory approval for the Symplicity Spyral Renal Denervation System

Medtronic advances pipeline with update on multi-organ denervation study and additional data recently presented at EuroPCR 2025

Large, international registry designed to expand real-world data for Symplicity blood pressure procedure for uncontrolled hypertension

Medtronic, a global leader in healthcare technology, announced today that it has received CE (Conformité Européenne) Mark approval for several expanded indications for the treatment of coronary...

Data from the largest study comparing drug-coated balloons presented as a late-breaking clinical trial at Cardiovascular Research Technologies 2025

St. Francis Hospital in New York performs the first patient procedure in clinical trial for coronary artery disease

Company recognized among top 52 global companies making positive social impact through core business strategy

Symplicity Spyral is the first renal denervation technology to be approved by the National Medical Products Administration; new, innovative, minimally invasive procedure uses radiofrequency energy to help reduce high blood pressure

Medtronic today announced it received a license from Health Canada for its Symplicity Spyral™ multi-electrode Renal Denervation (RDN) System. This is indicated for the management of essential...

Bifurcation using Onyx Frontier DES Medtronic announced today that it has received Food and Drug Administration (FDA) approval for the treatment of non-left main bifurcation lesions utilizing the...

Medtronic announced today that it has launched its newest drug-eluting coronary stent, the Onyx Frontier™ drug-eluting stent (DES), following recent CE Mark approval. The Onyx Frontier DES...